{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:17:52Z","timestamp":1792603072594,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejogrb.2024.10.059","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T16:32:05Z","timestamp":1730478725000},"page":"302-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and safety of different doses of mifepristone in the treatment of uterine fibroids: A meta-analysis"],"prefix":"10.1016","volume":"303","author":[{"given":"Xiaoxiao","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuqing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haofei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunping","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-4451","authenticated-orcid":false,"given":"Yefang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejogrb.2024.10.059_b0005","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.fertnstert.2021.02.040","article-title":"Vitamin D deficiency and uterine fibroids: an opportunity for treatment or prevention?","volume":"115","author":"Islam","year":"2021","journal-title":"Fertil Steril"},{"issue":"4","key":"10.1016\/j.ejogrb.2024.10.059_b0010","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.fertnstert.2022.01.037","article-title":"The epidemiology of uterine fibroids: where do we go from here?","volume":"117","author":"Harris","year":"2022","journal-title":"Fertil Steril"},{"issue":"4","key":"10.1016\/j.ejogrb.2024.10.059_b0015","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ajog.2006.02.020","article-title":"Health care resource use for uterine fibroid tumors in the United States","volume":"195","author":"Flynn","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ejogrb.2024.10.059_b0020","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0029-7844(97)00534-6","article-title":"Variation in the incidence of uterine leiomyoma among premenopausal women by age and race","volume":"90","author":"Marshall","year":"1997","journal-title":"Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.ejogrb.2024.10.059_b0025","doi-asserted-by":"crossref","first-page":"e052053","DOI":"10.1136\/bmjopen-2021-052053","article-title":"Epidemiology of uterine fibroid in black African women: a systematic scoping review","volume":"12","author":"Morhason-Bello","year":"2022","journal-title":"BMJ Open"},{"issue":"14","key":"10.1016\/j.ejogrb.2024.10.059_b0030","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejogrb.2024.10.059_b0035","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1210\/en.2009-1225","article-title":"Progesterone is essential for maintenance and growth of uterine leiomyoma","volume":"151","author":"Ishikawa","year":"2010","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.ejogrb.2024.10.059_b0040","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1210\/jc.2016-3527","article-title":"Versican proteolysis by ADAMTS proteases and its influence on sex steroid receptor expression in uterine leiomyoma","volume":"102","author":"Gueye","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ejogrb.2024.10.059_b0045","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0015-0282(02)03366-6","article-title":"Coordinated regulation of HOX gene expression in myometrium and uterine leiomyoma","volume":"78","author":"Cermik","year":"2002","journal-title":"Fertil Steril"},{"issue":"9252","key":"10.1016\/j.ejogrb.2024.10.059_b0050","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(00)03622-9","article-title":"Uterine fibroids","volume":"357","author":"Stewart","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejogrb.2024.10.059_b0055","article-title":"Selective progesterone receptor modulators (SPRMs) for uterine fibroids","volume":"2017","author":"Murji","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ejogrb.2024.10.059_b0060","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10616-021-00455-6","article-title":"The function role and synergic effect of syndecan-1 for mifepristone in uterine leiomyoma","volume":"73","author":"Shen","year":"2021","journal-title":"Cytotechnology"},{"issue":"S1","key":"10.1016\/j.ejogrb.2024.10.059_b0065","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s13224-016-0861-7","article-title":"Efficacy of use of long-term, low-dose mifepristone for the treatment of fibroids","volume":"66","author":"Kapur","year":"2016","journal-title":"J Obstetr Gynecol India"},{"issue":"1","key":"10.1016\/j.ejogrb.2024.10.059_b0070","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/02656736.2021.1922763","article-title":"Comparison between radiofrequency ablation combined with mifepristone and radiofrequency ablation for large uterine fibroids","volume":"38","author":"Hai","year":"2021","journal-title":"Int J Hyperth"},{"key":"10.1016\/j.ejogrb.2024.10.059_b0075","article-title":"Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery. International","volume":"75","author":"Carbonell Esteve","year":"2012","journal-title":"J Womens Health"},{"issue":"7","key":"10.1016\/j.ejogrb.2024.10.059_b0080","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejogrb.2024.10.059_b0085","doi-asserted-by":"crossref","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database of Systematic Reviews. 2019.","DOI":"10.1002\/14651858.ED000142"},{"issue":"3","key":"10.1016\/j.ejogrb.2024.10.059_b0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.mjafi.2017.02.013","article-title":"A randomized control trial to assess efficacy of Mifepristone in medical management of uterine fibroid","volume":"73","author":"Arora","year":"2017","journal-title":"Med J Armed Forces India"},{"issue":"1","key":"10.1016\/j.ejogrb.2024.10.059_b0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1479-828X.2008.00931.x","article-title":"Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial","volume":"49","author":"Bagaria","year":"2009","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"5","key":"10.1016\/j.ejogrb.2024.10.059_b0100","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/AOG.0b013e31818aa930","article-title":"Mifepristone for the treatment of uterine leiomyomas","volume":"112","author":"Carbonell Esteve","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ejogrb.2024.10.059_b0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pog.2009.11.001","article-title":"Mifepristona 5mg frente a 10mg diarios en el tratamiento del leiomioma. Ensayo cl\u00ednico aleatorizado","volume":"53","author":"Carbonell Esteve","year":"2010","journal-title":"Progresos de Obstetricia y Ginecolog\u00eda"},{"key":"10.1016\/j.ejogrb.2024.10.059_b0110","article-title":"Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial","volume":"115","author":"Carbonell Esteve","year":"2013","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.ejogrb.2024.10.059_b0115","article-title":"Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial. International","author":"Carbonell Esteve","year":"2013","journal-title":"J Womens Health"},{"key":"10.1016\/j.ejogrb.2024.10.059_b0120","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/649030","article-title":"Treatment of uterine myoma with 2.5 or 5 mg mifepristone daily during 3 months with 9 months posttreatment followup: randomized clinical trial","volume":"2013","author":"Carbonell","year":"2013","journal-title":"ISRN Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ejogrb.2024.10.059_b0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pog.2010.02.002","article-title":"Evoluci\u00f3n del leiomioma uterino despu\u00e9s del tratamiento con mifepristona. Ensayo cl\u00ednico aleatorizado","volume":"53","author":"Carbonell","year":"2010","journal-title":"Progresos de Obstetricia y Ginecolog\u00eda"},{"issue":"2","key":"10.1016\/j.ejogrb.2024.10.059_b0130","first-page":"243","article-title":"Low-dose mifepristone for uterine leiomyomata","volume":"101","author":"Eisinger","year":"2003","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ejogrb.2024.10.059_b0135","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jmig.2005.01.022","article-title":"Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas","volume":"12","author":"Eisinger","year":"2005","journal-title":"J Minim Invasive Gynecol"},{"issue":"8","key":"10.1016\/j.ejogrb.2024.10.059_b0140","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/humrep\/dep100","article-title":"Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial","volume":"24","author":"Engman","year":"2009","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.ejogrb.2024.10.059_b0145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejogrb.2011.12.018","article-title":"Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial","volume":"161","author":"Esteve","year":"2012","journal-title":"Eur J Obstetr Gynecol Reproductive Biol"},{"issue":"2","key":"10.1016\/j.ejogrb.2024.10.059_b0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijgo.2009.11.019","article-title":"Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone","volume":"109","author":"Feng","year":"2010","journal-title":"Int J Gynecol Obstet"},{"issue":"7","key":"10.1016\/j.ejogrb.2024.10.059_b0155","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.humpath.2010.11.003","article-title":"Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone","volume":"42","author":"Fiscella","year":"2011","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.ejogrb.2024.10.059_b0160","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/01.AOG.0000243776.23391.7b","article-title":"Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size","volume":"108","author":"Fiscella","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2024.10.059_b0165","unstructured":"Kulshrestha V, Kriplani A, Agarwal N, Sareen N, Garg P, Hari S, Thulkar J. Low dose mifepristone in medical management of uterine leiomyoma -An experience from a tertiary care hospital from north India. 2013."},{"issue":"7","key":"10.1016\/j.ejogrb.2024.10.059_b0170","doi-asserted-by":"crossref","first-page":"e6124","DOI":"10.1097\/MD.0000000000006124","article-title":"Different dosages of mifepristone versus enantone to treat uterine fibroids","volume":"96","author":"Liu","year":"2017","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.ejogrb.2024.10.059_b0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/ijgo.13102","article-title":"Epidemiology and management of uterine fibroids","volume":"149","author":"Giuliani","year":"2020","journal-title":"Int J Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.ejogrb.2024.10.059_b0180","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/ijerph18031066","article-title":"Uterine fibroids and diet","volume":"18","author":"Tinelli","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"10.1016\/j.ejogrb.2024.10.059_b0185","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3390\/cells12081117","article-title":"Progesterone signaling and uterine fibroid pathogenesis; molecular mechanisms and potential therapeutics","volume":"12","author":"Ali","year":"2023","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.ejogrb.2024.10.059_b0190","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1210\/endrev\/bnab039","article-title":"Comprehensive review of uterine fibroids: developmental origin, pathogenesis, and treatment","volume":"43","author":"Yang","year":"2022","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ejogrb.2024.10.059_b0195","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/cells11040647","article-title":"Progesterone actions and resistance in gynecological disorders","volume":"11","author":"Maclean","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejogrb.2024.10.059_b0200","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.2147\/DDDT.S212157","article-title":"Mifepristone inhibits IGF-1 signaling pathway in the treatment of uterine leiomyomas","volume":"13","author":"Shen","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"10.1016\/j.ejogrb.2024.10.059_b0205","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.fertnstert.2015.12.021","article-title":"Mifepristone inhibits extracellular matrix formation in uterine leiomyoma","volume":"105","author":"Patel","year":"2016","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.ejogrb.2024.10.059_b0210","article-title":"Mifepristone for uterine fibroids","volume":"2021","author":"Tristan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.ejogrb.2024.10.059_b0215","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/GCO.0b013e32832e07e8","article-title":"Clinical utility of progesterone receptor modulators and their effect on the endometrium","volume":"21","author":"Spitz","year":"2009","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ejogrb.2024.10.059_b0220","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/humupd\/dmm023","article-title":"Progesterone receptor modulators and the endometrium: changes and consequences\u2020","volume":"13","author":"Horne","year":"2007","journal-title":"Hum Reprod Update"},{"issue":"5","key":"10.1016\/j.ejogrb.2024.10.059_b0225","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.contraception.2009.12.012","article-title":"Mifepristone: where do we come from and where are we going?","volume":"82","author":"Spitz","year":"2010","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.ejogrb.2024.10.059_b0230","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod Pathol"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211524006055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211524006055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T23:52:28Z","timestamp":1734652348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211524006055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":46,"alternative-id":["S0301211524006055"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2024.10.059","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of different doses of mifepristone in the treatment of uterine fibroids: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2024.10.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}